Hvis behandling med disse lægemidler påbegyndes eller standses hos patienter i behandling med nateglinid, skal patienten observeres grundigt for ændringer i den glykæmiske kontrol.
When these medicinal products are administered to or withdrawn from patients receiving nateglinide, the patient should be observed closely for changes in glycaemic control.